Quantcast

Latest Virus-like particle Stories

2011-03-14 15:06:00

QUEBEC CITY, March 14 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Pierre Labbe, Chief Financial Officer will present a corporate update at the 23(rd) Annual Roth OC Growth Stock Conference on Tuesday, March 15, 2011 at 8:00 a.m. Pacific Time at The Ritz Carlton Laguna Niguel in Dana Point,...

2011-03-03 11:49:00

ROCKVILLE, Md., March 3, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that Maryland State Governor Martin O'Malley will visit the company's headquarters in Rockville, Maryland, on Monday, March 7, to celebrate the recently announced contract valued at up to $179 million. The Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human...

2011-03-01 07:30:00

ROCKVILLE, Md., March 1, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today that it has been awarded a contract valued at up to $179 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic...

2011-02-28 18:30:00

ROCKVILLE, Md., Feb. 28, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) announced today an agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to LG Life Sciences, Ltd. (LGLS). Under the agreement, LGLS receives an exclusive license to manufacture, develop and commercialize influenza vaccines using Novavax's recombinant VLP technology in South Korea. LGLS also receives a non-exclusive license to manufacture, develop and commercialize influenza...

2011-02-18 07:00:00

ROCKVILLE, Md., Feb. 18, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage biopharmaceutical company, today presented the final safety and immunogenicity results from its 2009 H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico at the invitation-only 7th World Health Organization Meeting (WHO) on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting was held at the WHO headquarters in Geneva, Switzerland where Dr. Gregory...

2011-02-15 06:00:00

QUEBEC CITY, Feb. 15 /PRNewswire-FirstCall/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Ms. Nathalie Landry, Vice President of Product Development, is invited to present at the 7(th) WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. The conference is being held at the World...

2011-02-10 07:00:00

QUEBEC CITY, Feb. 10 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that Mr. Andy Sheldon, President and Chief Executive Officer of Medicago will be presenting at the 13th Annual BIO CEO & Investor Conference. The conference is being held at the Waldorf Astoria in New York City from February 14(th)-15(th),...

2011-02-09 08:00:00

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Gregory Glenn, Chief Medical Officer of Novavax, will be presenting safety and immunogenicity data from its pivotal 2009 A/H1N1 virus-like particle (VLP) pandemic influenza vaccine clinical trial in Mexico, at the invitation-only 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. The meeting is being held February 17-18, 2011 at...

2011-02-01 06:19:00

- Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - -Company's VLP induced the production of antibodies that cross react with multiple strains of influenza- QUEBEC CITY, Feb. 1 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results...

2011-01-11 07:00:00

-Proposed development of a single dose H5N1 influenza vaccine which could be rapidly and widely administered in the case of avian pandemic flu outbreak- -Approved for Public Release, Distribution Unlimited- QUEBEC CITY, Jan. 11 /PRNewswire/ - Medicago Inc. (TSX: MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it was selected to collaborate...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.